First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.

Georgina V Long Evan J LipsonF Stephen HodiPaolo Antonio Ascierto James M G LarkinChristopher LaoJean-Jacques GrobFlavia EjzykowiczAndriy MoshykViviana Garcia-HortonZheng-Yi Zhou Yiqiao XinJennell PalaiaLaura McDonaldSarah KeidelAnthony SalvatoreDivya PatelLeon A Sakkal Hussein A Tawbi Dirk Schadendorf

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

Nivolumab plus relatlimab demonstrated similar efficacy to nivolumab plus ipilimumab in the overall population, including most-but not all-subgroups, and improved safety in patients with untreated advanced melanoma. Results should be interpreted with caution.

Keyphrases

clinical trial
study protocol
electronic health record
phase iii
machine learning
deep learning
basal cell carcinoma
smoking cessation